Modeling and protein engineering studies of active and inactive states of human dopamine D2 receptor (D2R) and investigation of drug/receptor interactions

Molecular Diversity

Volumn 19, Issue 2, 2015, Pages 321-332

  Salmas, Ramin Ekhteiari ^a   Yurtsever, Mine ^a   Stein, Matthias ^b   Durdagi, Serdar ^b,c  

^a ISTANBUL TECHNICAL UNIVERSITY   (Turkey)

^b MAX PLANCK INSTITUTE FOR DYNAMICS OF COMPLEX TECHNICAL SYSTEMS   (Germany)

^c BAHCESEHIR UNIVERSITY   (Turkey)

Author keywords

Alanine scanning mutagenesis; Dopamine D2 receptor; G protein coupled receptors; Homology modeling; Molecular docking simulations

Indexed keywords

DOPAMINE 2 RECEPTOR; LIGAND; PROTEIN BINDING;

AMINO ACID SEQUENCE; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DRUG DEVELOPMENT; GENETICS; HUMAN; HYDROGEN BOND; METABOLISM; MOLECULAR GENETICS; PROCEDURES; PROTEIN ENGINEERING; REPRODUCIBILITY; SEQUENCE ALIGNMENT;

AMINO ACID SEQUENCE; DRUG DISCOVERY; HUMANS; HYDROGEN BONDING; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTORS, DOPAMINE D2; REPRODUCIBILITY OF RESULTS; SEQUENCE ALIGNMENT;

EID: 84939987863     PISSN: 13811991     EISSN: 1573501X     Source Type: Journal    
DOI: 10.1007/s11030-015-9569-3     Document Type: Article

References (61)

1. Römpler H, Stäubert C, Thor D, Schulz A, Hofreiter M, Schöneberg T (2007) G protein-coupled time travel: evolutionary aspects of GPCR research. Mol Interv 7:17–25. doi:10.1124/mi.7.1.5
2. Congreve M, Marshall F (2010) The impact of GPCR structures on pharmacology and structure-based drug design. Br J Pharmacol 159:986–996. doi:10.1111/j.1476-5381.2009.00476.x
3. Overington JP, Al-Lazikani B, Hopkins AL (2006) How many drug targets are there? Nat Rev Drug Discov 5:993–996. doi:10.1038/nrd2199
4. Lagerström MC, Schiöth HB (2008) Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov 7:339–357. doi:10.1038/nrd2592
5. Rasmussen SGF, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, Calinski D, Mathiesen JM, Shah ST, Lyons JA, Caffrey M, Gellman SH, Steyaert J, Skiniotis G, Weis WI, Sunahara RK, Kobilka BK (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature 477:549–555. doi:10.1038/nature10361
6. Jaakola V-P, Griffith MT, Hanson MA, Cherezov V, Chien EY, Lane JR, Ijzerman AP, Stevens RC (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322:1211–1217. doi:10.1126/science.1164772
7. Haga K, Kruse AC, Asada H, Yurugi-Kobayashi T, Shiroishi M, Zhang C, Weis WI, Okada T, Kobilka BK, Haga T, Kobayashi T (2012) Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature 482:547–551. doi:10.1038/nature10753
8. Park JH, Scheerer P, Hofmann KP, Choe HW, Ernst OP (2008) Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature 454:183–187. doi:10.1038/nature07063
9. Scheerer P, Park JH, Hildebrand PW, Kim YJ, Krauss N, Choe HW, Hofmann KP, Ernst OP (2008) Crystal structure of opsin in its G-protein-interacting conformation. Nature 455:497–502. doi:10.1038/nature07330
10. Jackson DM, Westlind-Danielsson A (1994) Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol Ther 64:291–370. doi:10.1016/0163-7258(94)90041-8
11. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189–225. doi:10.1186/1471-2296-12-32
12. Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261:717–719. doi:10.1038/261717a0
13. Creese I, Burt DR, Snyder SH (1996) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. J Neuropsychiatry Clin Neurosci 8:223–226. doi:10.1126/science.3854
14. Beaulieu J-M, Gainetdinov RR (2011) The physiology, signaling, and pharmacology of dopamine receptors. Pharmacol Rev 63:182–217. doi:10.1124/pr.110.002642.182
15. Greengard P (2001) The neurobiology of dopamine signaling. Biosci Rep 21:247–269
16. Oerther S, Ahlenius S (2000) Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat. J Pharmacol Exp Ther 292:731–736
17. Patel S, Freedman S, Chapman KL, Emms F, Fletcher AE, Knowles M, Marwood R, Mcallister G, Myers J, Curtis N, Kulagowski JJ, Leeson PD, Ridgill M, Graham M, Matheson S, Rathbone D, Watt AP, Bristow LJ, Rupniak NM, Baskin E, Lynch JJ, Ragan CI (1997) Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther 283:636–647
18. Rauser L, Savage JE, Meltzer HY, Roth BL (2001) Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 299:83–89
19. The UniProt Consortium (2014) Activities at the universal protein resource (UniProt). Nucleic Acids Res 42:D191–D198
20. Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W, Lipman DJ (1997) Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 25:3389–3402. doi:10.1093/nar/25.17.3389
21. Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234:779–815. doi:10.1006/jmbi.1993.1626
22. Thompson JD, Higgins DG, Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680. doi:10.1093/nar/22.22.4673
23. Jacobson MP, Pincus DL, Rapp CS, Day TJ, Honig B, Shaw DE, Friesner RA (2004) A hierarchical approach to all-atom protein loop prediction. Proteins Struct Funct Genet 55:351–367. doi:10.1002/prot.10613
24. Stein A, Kortemme T (2013) Improvements to Robotics-Inspired Conformational Sampling in Rosetta. PLoS One. doi:10.1371/journal.pone.0063090
25. Kim DE, Chivian D, Baker D (2004) Protein structure prediction and analysis using the Robetta server. Nucleic Acids Res. doi:10.1093/nar/gkh468
26. Laskowski RA, Rullmannn JA, MacArthur MW, Kaptein R, Thornton JM (1996) AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR 8:477–486. doi:10.1007/BF00228148
27. Madhavi Sastry G, Adzhigirey M, Day T, Annabhimoju R, Sherman W (2013) Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J Comput Aided Mol Des 27:221–234. doi:10.1007/s10822-013-9644-8
28. Jorgensen WL, Tirado-Rives J (1988) The OPLS potential functions for proteins. Energy minimizations for crystals of c‘yclic peptides and crambin. J Am Chem Soc 110:1657–1666. doi:10.1021/ja00214a001
29. Li H, Robertson AD, Jensen JH (2005) Very fast empirical prediction and rationalization of protein pK a values. Proteins Struct Funct Genet 61:704–721. doi:10.1002/prot.20660
30. Irwin JJ, Shoichet BK (2005) ZINC—a free database of commercially available compounds for virtual screening. J Chem Inf Model 45:177–182. doi:10.1021/ci049714+
31. Chen IJ, Foloppe N (2010) Drug-like bioactive structures and conformational coverage with the ligprep/confgen suite: comparison to programs MOE and catalyst. J Chem Inf Model 50:822–839. doi:10.1021/ci100026x
32. Tubert-Brohman I, Sherman W, Repasky M, Beuming T (2013) Improved docking of polypeptides with glide. J Chem Inf Model 53:1689–1699. doi:10.1021/ci400128m
33. Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105:6474–6487. doi:10.1021/jp003919d
34. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R (2006) Novel procedure for modeling ligand/receptor induced fit effects. J Med Chem 49:534–553. doi:10.1021/jm050540c
35. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions.1. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11:425–445
36. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, Banks JL (2004) Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem 47:1750–1759. doi:10.1021/jm030644s
37. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem 49:6177–6196. doi:10.1021/jm051256o
38. Hanson MA, Cherezov V, Griffith MT, Roth CB, Jaakola VP, Chien EY, Velasquez J, Kuhn P, Stevens RC (2008) A specific cholesterol binding site is established by the 2.8 Å Structure of the human beta 2-adrenergic receptor. Structure 16:897–905. doi:10.1016/j.str.2008.05.001
39. Malo M, Brive L, Luthman K, Svensson P (2012) Investigation of D 2 receptor-agonist interactions using a combination of pharmacophore and receptor homology modeling. ChemMedChem 7:471–482. doi:10.1002/cmdc.201100545
40. McRobb FM, Capuano B, Crosby IT, Chalmers DK, Yuriev E (2010) Homology modeling and docking evaluation of aminergic g protein-coupled receptors. J Chem Inf Model 50:626–637. doi:10.1021/ci900444q
41. Shi L, Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 42:437–467. doi:10.1146/annurev.pharmtox.42.091101.144224
42. Kim H, Park H (2003) Protein secondary structure prediction based on an improved support vector machines approach. Protein Eng 16:553–560. doi:10.1093/protein/gzg072
43. Homan EJ, Wikstrom HV, Grol CJ (1999) Molecular modeling of the dopamine D2 and serotonin 5-HT1A receptor binding modes of the enantiomers of 5-OMe-BPAT. Bioorg Med Chem 7:1805–20
44. Javitch JA, Fu D, Chen J, Karlin A (1995) Mapping the binding-site crevice of the dopamine D2 receptor by the substituted-cysteine accessibility method. Neuron 14:825–831. doi:10.1016/0896-6273(95)90226-0
45. Wang CD, Gallaher TK, Shih JC (1993) Site-directed mutagenesis of the serotonin 5-hydroxytrypamine2 receptor: identification of amino acids necessary for ligand binding and receptor activation. Mol Pharmacol 43:931–940
46. Shi L, Javitch JA (2004) The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 101:440–445. doi:10.1073/pnas.2237265100
47. Shi L, Simpson MM, Ballesteros JA, Javitch JA (2001) The first transmembrane segment of the dopamine D2 receptor: accessibility in the binding-site crevice and position in the transmembrane bundle. Biochemistry 40:12339–12348. doi:10.1021/bi011204a
48. Javitch JA, Ballesteros JA, Chen J, Chiappa V, Simpson MM (1999) Electrostatic and aromatic microdomains within the binding-site crevice of the D2 receptor: contributions of the second membrane-spanning segment. Biochemistry 38:7961–7968. doi:10.1021/bi9905314
49. Fu D, Ballesteros Ja, Weinstein H, Chen J, Javitch JA (1996) Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. Biochemistry 35:11278–11285. doi:10.1021/bi960928x
50. Javitch JA, Fu D, Chen J (1995) Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. Biochemistry 34:16433–16439. doi:10.1021/bi00050a026
51. Javitch JA, Ballesteros JA, Weinstein H, Chen J (1998) A cluster of aromatic residues in the sixth membrane-spanning segment of the dopamine D2 receptor is accessible in the binding-site crevice. Biochemistry 37:998–1006. doi:10.1021/bi972241y
52. Mansour A, Meng F, Meador-Woodruff JH, Taylor LP, Civelli O, Akil H (1992) Site-directed mutagenesis of the human dopamine D2 receptor. Eur J Pharmacol 227:205–214
53. Cox BA, Henningsen RA, Spanoyannis A, Neve RL, Neve KA (1992) Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors. J Neurochem 59:627–635. doi:10.1111/j.1471-4159.1992.tb09416.x
54. Cho W, Taylor LP, Mansour A, Akil H (1995) Hydrophobic residues of the D2 dopamine receptor are important for binding and signal transduction. J Neurochem 65:2105–2115
55. Coley C, Woodward R, Johansson AM, Strange PG, Naylor LH (2000) Effect of multiple serine/alanine mutations in the transmembrane spanning region V of the D2 dopamine receptor on ligand binding. J Neurochem 74:358–366. doi:10.1046/j.1471-4159.2000.0740358.x
56. Durdagi S, Kapou A, Kourouli T, Andreou T, Nikas SP, Nahmias VR, Papahatjis DP, Papadopoulos MG, Mavromoustakos T (2007) The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1’ position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2. J Med Chem 50:2875–2885
57. Potamitis C, Zervou M, Katsiaras V, Zoumpoulakis P, Durdagi S, Papadopoulos MG, Hayes JM, Grdadolnik SG, Kyrikou I, Argyropoulos D, Vatougia G, Mavromoustakos T (2009) Antihypertensive drug valsartan in solution and at the AT(1) receptor: conformational analysis, dynamic NMR spectroscopy, in silico docking, and molecular dynamics simulations. J Chem Inf Model 49:726–739
58. Mavromoustakos T, Durdagi S, Koukoulitsa C, Simcic M, Papadopoulos MG, Hodoscek M, Grdadolnik SG (2011) Strategies in the rational drug design. Curr Med Chem 18:2517–2530
59. Durdagi S, Papadopoulos MG, Zoumpoulakis PG, Koukoulitsa C, Mavromoustakos T (2010) A computational study on cannabinoid receptors and potent bioactive cannabinoid ligands: homology modeling, docking, de novo drug design and molecular dynamics analysis. Mol Divers 14:257–276
60. Durdagi S, Papadopoulos MG, Papahatjis DP, Mavromoustakos T (2007) Combined 3D QSAR and molecular docking studies to reveal novel cannabinoid ligands with optimum binding activity. Bioorg Med Chem Lett 17:6754–6763
61. Durdagi S, Reis H, Papadopoulos MG, Mavromoustakos T (2008) Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors. Bioorg Med Chem 16:7377–7387